Synthetic steroid angigestagennoe means (blocks the action of progesterone at the receptor level) progestogenic activity is not. Marked antagonism with corticosteroids (due to competition on the level of communication with the receptors). Increases sustanon cycle contractility of the myometrium. stimulating the release of IL-8 in cells and horiodetsidualnyh myometrium increasing sensitivity to prostaglandins. As a result of the drug takes place decidua desquamation and removal of the ovum.
- Interruption of uterine pregnancy of early terms (up to 42 days of amenorrhea) in conjunction with misoprostol.
- Training and induction of labor.
- It has a history of hypersensitivity to mifepristone
- Adrenal insufficiency and prolonged therapy glkzhokortikosteroidnaya
- Acute or chronic renal and / or hepatic impairment
- Uterine fibroids (for a given dosage form)
- Anemia (hemoglobin level of less than 100 g / l)
- Disorders of hemostasis (including previous treatment with anticoagulants)
- Acute pelvic inflammatory disease
- The presence of heavy ekstragenitalyyuy pathology.
- Smoking women older than 35 years old without consulting a therapist.
For medical abortion:
a suspicion of an ectopic pregnancy,
pregnancy not confirmed by clinical studies; exceeding the deadline by 42 days of amenorrhea,
pregnancy, appeared at the background of intrauterine contraception, or after the cancellation of hormonal contraception.
For the training and induction of labor:
preeclampsia, severe preeclampsia, eclampsia, preterm or post-term pregnancy, the discrepancy pelvis maternal and fetal head, abnormal fetal position, spotting during pregnancy from the genital tract unknown etiology, premature rupture of membranes, severe hemolytic fetal disease.
To use caution in chronic obstructive pulmonary disease, asthma, hypertension, heart rhythm disturbances, heart failure.
Dosing and Administration
The drug should be used sustanon cycle only in hospitals that have a properly trained medical personnel and necessary equipment.
For the medical termination of early pregnancy.
600 mg of mifepristone (three 200 mg tablets) taken orally once in the presence of a doctor, after 1-1.5 hours after a meal (continental breakfast), washed down with 100 ml of water. Within 36-48 hours after mifepristone the patient should come to the hospital for receiving misoprostol 400 mcg. After administration of misoprostol must be dynamic medical supervision for 2 hours. After 10-14 days to re-conducted clinical examination and ultrasound control, if necessary, to determine the level of human chorionic gonadotropin to confirm that there was a miscarriage.
In the absence of effect of the drug on day 14 (incomplete abortion or ongoing pregnancy) conducted vakuumaspiratsiyu with subsequent histological examination of the aspirate.
For the training and induction of labor:
a single oral 200 mg of mifepristone (one tablet) in the presence of a doctor. After 24 hours, 200 mg of repeated reception. After 48-72 hours assesses the state of the birth canal and, if necessary, be appointed by prostaglandins or oxytocin.
associated with taking mifepristone. The feeling of discomfort in the abdomen, weakness, headache, nausea and vomiting, dizziness, pyrexia, rash.
Related medical abortion procedure. Bloody discharge from the genital tract. Pain in the lower abdomen. Exacerbation of inflammatory processes of the uterus and appendages.
mifepristone at doses up to 2 g does not cause unwanted reactions. In cases of overdose adrenal insufficiency may occur.
Interaction with other drugs
should be avoided nonsteroidal anti-inflammatory drugs (NSAIDs). At simultaneous reception of mifepristone and glucocorticosteroid medications need to increase the dose of the latter.
Patients using mifepristone for termination of early pregnancy should be informed that if the effect on the 10-14 day of the drug is not available (incomplete abortion or ongoing pregnancy), pregnancy, be sure to interrupt the other way, because it is possible the formation of congenital malformations in fetus.
Use of the drug requires prevention of Rh-alloimmunization and other general sustanon cycle activities related to abortion.
Breast-feeding should be discontinued 3 days after mifepristone medical abortion in the case.
The use of mifepristone for the preparation of the cervix for childbirth does not affect the subsequent lactation.